Comprehensive analysis of DOK family genes expression, immune characteristics, and drug sensitivity in human tumors

Janas, 2011, Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation, Mol Cell Biol, 31, 2552, 10.1128/MCB.05045-11 Mashima, 2013, Dok adaptors play anti-inflammatory roles in pulmonary homeostasis, Genes Cells, 18, 56, 10.1111/gtc.12016 Carpino, 1997, p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells, Cell, 88, 197, 10.1016/S0092-8674(00)81840-1 Yamanashi, 1997, Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, Dok, Cell, 88, 205, 10.1016/S0092-8674(00)81841-3 Mashima, 2009, The roles of Dok family adapters in immunoreceptor signaling, Immunol Rev, 232, 273, 10.1111/j.1600-065X.2009.00844.x Guittard, 2018, Evolutionary and expression analyses reveal a pattern of ancient duplications and functional specializations in the diversification of the Downstream of Kinase (DOK) genes, Dev Comp Immunol, 84, 193, 10.1016/j.dci.2018.02.011 Grimm, 2001, Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation, J Cell Biol, 154, 345, 10.1083/jcb.200102032 Favre, 2003, DOK4 and DOK5: new Dok-related genes expressed in human T cells, Genes Immun, 4, 40, 10.1038/sj.gene.6363891 He, 2018, Methylation-associated DOK1 and DOK2 down-regulation: potential biomarkers for predicting adverse prognosis in acute myeloid leukemia, J Cell Physiol, 233, 6604, 10.1002/jcp.26271 Chen, 2019, Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis, J Clin Invest, 129, 215, 10.1172/JCI99699 An, 2011, Mutational and expressional analysis of a haploinsufficient tumor suppressor gene DOK2 in gastric and colorectal cancers, APMIS, 119, 562, 10.1111/j.1600-0463.2011.02749.x Friedrich, 2016, Burgermeister, Subcellular compartmentalization of docking protein-1 contributes to progression in colorectal cancer, EBioMedicine, 8, 159, 10.1016/j.ebiom.2016.05.003 Ghanem, 2014, mRNA expression of DOK1-6 in human breast cancer, World J Clin Oncol, 5, 156, 10.5306/wjco.v5.i2.156 Heidarizadi, 2020, Study of DOK4 gene expression and promoter methylation in sporadic breast cancer, Neoplasma, 67, 916, 10.4149/neo_2020_190811N747 Wu, 2019, Integration and analysis of CPTAC proteomics data in the context of cancer genomics in the cBioPortal, Mol Cell Proteomics, 18, 1893, 10.1074/mcp.TIR119.001673 Li, 2017, TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells, Cancer Res, 77, e108, 10.1158/0008-5472.CAN-17-0307 Gérard, 2009, Dok-4 is a novel negative regulator of T cell activation, J Immunol, 182, 7681, 10.4049/jimmunol.0802203 Huang, 2017, Co-expression and significance of Dok2 and Ras p21 protein activator 1 in breast cancer, Oncol Lett, 14, 5386 Fang, 2018, Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs, Cancer Res, 78, 631, 10.1158/0008-5472.CAN-17-1492 Deshpande, 2018, Region-specific Dok2 overexpression associates with poor prognosis in human astrocytoma, Mol Neurobiol, 55, 402, 10.1007/s12035-016-0324-2 Downer, 2013, Differential role of Dok1 and Dok2 in TLR2-induced inflammatory signaling in glia, Mol Cell Neurosci, 56, 148, 10.1016/j.mcn.2013.04.007 Oki, 2005, Dok1 and SHIP act as negative regulators of v-Abl-induced pre-B cell transformation, proliferation and Ras/Erk activation, Cell Cycle, 4, 310, 10.4161/cc.4.2.1417 Tuna, 2020, Analysis of the DOK1 gene in breast cancer, Mol Biol Rep, 47, 1605, 10.1007/s11033-020-05247-3 Mercier, 2011, Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer, Mol Oncol, 5, 438, 10.1016/j.molonc.2011.07.003 Saulnier, 2012, Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers, Int J Cancer, 130, 2484, 10.1002/ijc.26299 Berger, 2010, Identification of DOK genes as lung tumor suppressors, Nat Genet, 42, 216, 10.1038/ng.527 Carneiro, 2008, Molecular targets and biological modifiers in gastric cancer, Semin Diagn Pathol, 25, 274, 10.1053/j.semdp.2008.07.004 Niki, 2004, Role of Dok-1 and Dok-2 in leukemia suppression, J Exp Med, 200, 1689, 10.1084/jem.20041306 Zhang, 2019, Prognostic role of DOK family adapters in acute myeloid leukemia, Cancer Gene Ther, 26, 305, 10.1038/s41417-018-0052-z Ueta, 2020, DOK7 Gene therapy enhances neuromuscular junction innervation and motor function in aged mice, iScience, 23, 10.1016/j.isci.2020.101385 Bissay, 2019, Phenotypic differences in 2 unrelated cases carrying identical DOK7 mutations, J Clin Neuromuscul Dis, 21, 30, 10.1097/CND.0000000000000246 Finsterer, 2019, Congenital myasthenic syndromes, Orphanet J Rare Dis, 14, 57, 10.1186/s13023-019-1025-5 Chen, 2017, The downstream of tyrosine kinase 7 is reduced in lung cancer and is associated with poor survival of patients with lung cancer, Oncol Rep, 37, 2695, 10.3892/or.2017.5538 Heyn, 2013, DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker, Carcinogenesis, 34, 102, 10.1093/carcin/bgs321 Siouda, 2012, Transcriptional regulation of the human tumor suppressor DOK1 by E2F1, Mol Cell Biol, 32, 4877, 10.1128/MCB.01050-12 Choi, 2018, Intratumoral heterogeneity of somatic mutations for NRIP1, DOK1, ULK1, ULK2, DLGAP3, PARD3 and PRKCI in colon cancers, Pathol Oncol Res, 24, 827, 10.1007/s12253-017-0297-0 Kim, 2011, Mutational analysis of DOK2 tumor suppressor gene in acute leukemias, Leuk Res, 35, e87, 10.1016/j.leukres.2011.01.027 Bevilacqua, 2017, Congenital Myasthenic syndrome due to DOK7 mutations in a family from Chile, Eur J Transl Myol, 27, 6832, 10.4081/ejtm.2017.6832 Li, 2008, Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy, J Natl Cancer Inst, 100, 672, 10.1093/jnci/djn123 Creighton, 2009, Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features, Proc Natl Acad Sci U S A, 106, 13820, 10.1073/pnas.0905718106 Lum, 2013, Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis, Gynecol Oncol, 130, 369, 10.1016/j.ygyno.2013.05.002 Klemm, 2015, Microenvironmental regulation of therapeutic response in cancer, Trends Cell Biol, 25, 198, 10.1016/j.tcb.2014.11.006 Steinman, 2002, Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance, Proc Natl Acad Sci U S A, 99, 351, 10.1073/pnas.231606698 Phillips, 2015, Preferential expansion of pro-inflammatory Tregs in human non-small cell lung cancer, Cancer Immunol Immunother, 64, 1185, 10.1007/s00262-015-1725-1 Pan, 2020, Promising key genes associated with tumor microenvironments and prognosis of hepatocellular carcinoma, World J Gastroenterol, 26, 789, 10.3748/wjg.v26.i8.789 Xu, 2020, Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma, PeerJ, 8, e9530, 10.7717/peerj.9530 Murri, 2008, The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer, Br J Cancer, 99, 1013, 10.1038/sj.bjc.6604667 Li, 2019, Docking protein-1 promotes inflammatory macrophage signaling in gastric cancer, Oncoimmunology, 8, e1649961, 10.1080/2162402X.2019.1649961